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ac.uk (P. Taylor), agibson@medphys.ucl.ac.uk (A.P. GibComputer-assisted diagnosis (CAD) describes a diverse, heterogeneous range of applications rather than a
single entity. The aims and functions of CAD systems vary considerably and comparing studies and sys-
tems is challenging due to methodological and design differences. In addition, poor study quality and
reporting can reduce the value of some publications. Meta-analyses of CAD are therefore difﬁcult and
may not provide reliable conclusions. Aiming to determine the major sources of heterogeneity and
thereby what CAD researchers could change to allow this sort of assessment, this study reviews a sample
of 147 papers concerning CAD used with imaging for cancer diagnosis. It discusses sources of variability,
including the goal of the CAD system, learning methodology, study population, design, outcome mea-
sures, inclusion of radiologists, and study quality. Based upon this evidence, recommendations are made
to help researchers optimize the quality and comparability of their trial design and reporting.
 2011 Elsevier Inc. All rights reserved.1. Introduction
The term computer-assisted diagnosis or detection (CAD) re-
lates to a variety of programs aiming to help physicians in their
diagnostic task. This can vary from expert systems which contain
specialized knowledge, to image analysis systems, to alerting sys-
tems working with medical records. Proponents of CAD claim it
has great potential to assist physicians, overcoming the limitations
of human short-term memory, distraction and fatigue; improving
their ability to do calculations and make interpretations of data;
and helping prevent bias and preconceptions affecting decisions
[1]. The error rate in radiology has been estimated as 2–20% for
clinically signiﬁcant or major errors [2], and in a recent survey of
more than 300 radiologists from 32 different countries, 91% re-
ported making 1–15 errors per year [3]. Despite this, CAD is not
yet widely used clinically outside of the US [4]. Several diagnostic
imaging CAD systems have been approved by the US Food and
Drug Administration, largely to help in screening situations [5],
and the situation has been encouraged by coverage from the major
US health insurers [6], but these systems are not widespread in
Europe. In the UK Breast Screening Programme, for example, two
radiologists look independently at each case. Although CAD hasll rights reserved.
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son).been proposed as an alternative to human second reading, con-
cerns about CAD accuracy and excessive false positive results have
led to low conﬁdence in these commercial systems [5]. Formal sys-
tematic analyses of their performance and that of newer CAD sys-
tems could therefore be useful in updating physicians about the
progress that has been made in CAD system development.
However, creating such a source of information is a complex
matter. This review arose from an attempt to try to quantify the
beneﬁt CAD can offer [7]: numerous challenges were encountered
when trying to pool and assess the results of various studies. Eval-
uating CAD as an entity is problematic because it is not a single,
uniform, easily deﬁnable body of work. There are numerous types
of CAD software, created using various machine learning method-
ologies, applicable in many different situations, being tested
against a variety of ‘gold standard’ diagnoses. This heterogeneity
causes problems when trying to assess whether using CAD is
worthwhile: meta-analyses are restricted to small groups of stud-
ies on systems with similar features, and even these may encoun-
ter problems in terms of the comparability of the trial design,
population used, comparison test, and the data reported.
This article examines the variability of CAD systems and trials,
looking at sources of heterogeneity arising at different steps during
the experimental process (see Fig. 1) and the resultant implications
for aggregating and interpreting the data. By doing this, we high-
light areas in which researchers can optimize their work for the
beneﬁt of comparative studies and, based on this evidence, we pro-
duce a set of recommendations to help ensure CAD studies are of a
suitable quality and are more likely to be comparable with other
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Fig. 1. Structure of the review. Recommendation numbers (see Section 4.1) are
shown in square brackets within the relevant sections.
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ine a sample of studies focusing on CAD software used with diag-
nostic medical imaging for cancer and discuss the differences
between CAD systems, the ways they are tested, and how the
results are reported.
2. Methods
A systematic review of CAD papers in the area of diagnostic
imaging for cancer provided source data for the assessment of
the heterogeneity in CAD systems and trials. We have previously
published results generated from this same research examining
the beneﬁt of CAD in various cancer diagnosis applications [7].
2.1. Information sources
The online databases Medline, EMBASE, IEEExplore, SCOPUS,
Web of Science, Science Direct, and CINAHL/EBSCO were searched
using the terms: (‘‘computer analysis’’ OR ‘‘computer-assisted diagno-
sis’’ OR ‘‘computer-assisted radiography’’ OR ‘‘computer-aided diagno-
sis’’ OR ‘‘computer-assisted detection’’ OR ‘‘computer-aided detection’’)
AND (imaging OR image OR scan OR scanning) AND (diagnosis) or
variants of these terms speciﬁc to the database searched (e.g.,
MeSH terms such as ‘‘diagnosis, computer-assisted’’ were used with
Medline). Papers published in journals or conference proceedings
between January 1990 and January 2010 were considered, and
non-English language papers whose full text was not available
were not included.
2.2. Study selection
The papers retrieved were initially ﬁltered to remove duplicates
and those that were not relevant. The abstracts of the remaining
papers were then searched for the terms ‘sensitivity’ and ‘speciﬁc-
ity’, and those not containing these terms were removed. The full
text of the selected papers was then located and searched in rela-
tion to the inclusion and exclusion criteria.
The criteria for inclusion were studies reporting on CAD systems
workingwith data frommedical imaging in humans for the purpose
of cancer diagnosis; studies reporting data ﬁrst-hand (i.e., not re-
viewpapers); studies includingP20patients (this numberwas cho-
sen to avoid papers that form part of a series of case studies and to
exclude studieswith low statistical power, yet allow a good breadthof studies to be included); studies including data on the sensitivity
and speciﬁcity of the CAD system’s diagnosis. Studies focusing on
ex vivo data (e.g., histology); non-imaging recordings (e.g., electro-
encephalogram, electrocardiogram); computer assisted surgery,
surgical planning or surgical navigation; and studies focusing on
prognosis rather than diagnosis were excluded. Papers reporting
duplicate results were not used; similarly, where research groups
had published several studies about the same CAD system, only
the most recent report of their system was included.
2.3. Analysis
Sensitivity and speciﬁcity data were extracted from the articles
comprising the sample. The area under the receiver-operating
characteristics curve was not used as a measure because less than
half of the review sample reported this ﬁgure. The diagnostic odds
ratio (DOR) and accuracy – two different ways of calculating a sin-
gle measure that takes into account both sensitivity and speciﬁcity
– were calculated using the equations below.
The DOR is a measure of the discriminative and diagnostic
power of a test; it is a ratio of the odds of a positive result in people
with the disease to the odds of a positive test result in people with-
out the diseased and is deﬁned as [8]:
sensitivity=ð1 sensitivityÞ
ð1 specificityÞ=specificity
The overall accuracy of a test reﬂects the number of correct
judgments (both positive and negative) and is deﬁned as:
ðsensitivityÞðprevalenceÞ þ ðspecificityÞð1 prevalenceÞ
Sensitivity, speciﬁcity and accuracy were not Normally distrib-
uted, and an arcsine-root transformation was applied to create a
more Gaussian distribution and allow the use of parametric statis-
tics [9].
Analysis of variance to check for differences in results and tests to
check for correlations between aspects of the data were performed
using SPSS Statistics 17.0 (SPSS Inc., an IBM Company, Chicago, IL,
USA). The threshold for statistical signiﬁcance was set at P < 0.05.
The quality of studies was determined using the Quality
Assessment Tool for Diagnostic Accuracy Studies (QUADAS) tool
for assessment of studies of diagnostic accuracy included in system-
atic reviews [10].
3. Results
3.1. The CAD systems
There were 147 studies reviewed for this paper (see Fig. 2). The
imagingmodalities used with CAD included X-ray (including mam-
mography), ultrasound (including elastography and Doppler), com-
puted tomography (CT), magnetic resonance imaging (MRI),
endoscopy and CT colonography (CTC), dermatologic imaging, opti-
cal tomography, and scintigraphy, looking for cancers of the breast,
lung, liver, pancreas, prostate, bowel, endometrium, skin, neck, and
head. Primary cancers, metastases, and ‘difﬁcult’ (interval, missed,
or disputed) cancers were all included.
This section highlights the fundamental differences between
CAD systems that researchers should be aware of when assessing
utility and considering comparisons of results. These factors con-
tribute to recommendation 1 in Section 4.1.
3.1.1. CAD aims
A major source of variation between CAD systems is their diag-
nostic aim. There are systems that act as screeners, trying to detect
any abnormalities, while other systems are more concerned with
Potentially relevant CAD studies identified 
by database search (n=8963)
Studies retrieved for abstract evaluation 
(n=3385)
Studies selected for analysis (n=147)
Studies discarded due to:
• Duplicates (n=43)
• Sensitivity/specificity missing 
(n=226)
• Review article (n=22)
• Not CAD (n=30)
• Not enough patients (n=37)
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• Non-English text, no full text (n=8)
Studies discarded due to being not 
relevant/duplicates (n=5578)
Studies retrieved for full text evaluation 
(n=588)
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in the abstract or being abstract only 
(n=2797)
Fig. 2. Study data ﬂow.
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Fig. 3. Pareto chart showing the diagnostic aims of included CAD systems.
392 L.H. Eadie et al. / Journal of Biomedical Informatics 45 (2012) 390–397the diagnosis of suspicious areas: i.e., whether a speciﬁc lesion is
benign or malignant. Some systems take this diagnosis further,
by trying to determine which of a number of potential diseases is
found in the image in question. In the sample of 147 studies used
in this paper, 43 (29%) described screening-type CAD systems, 90
(61%) described systems determining whether regions were malig-
nant or benign, and the remaining 14 studies (10%) tested systems
that produced a diagnosis of speciﬁc disease type (Fig. 3). This dis-
tinction between CAD systems was frequently related to the type
of image used as input, discussed in Section 3.3.
Some CAD systems are designed to look for speciﬁc subtypes of
cancer. A good example is the split between microcalciﬁcations,
architectural distortions, and masses in breast imaging. While
there are systems that look for all types of abnormality, there are
also those that have chosen just one as a focus. Microcalciﬁcations
are usually detected more reliably than masses on mammograms,
so systems that search only for them (12% of the sample) haveslightly higher accuracy on average (81 versus 79) and so can ap-
pear to be more useful than those that look for all suspicious fea-
tures. Alternatively, systems aiming to detect masses (41% of the
sample) offer a research challenge in improving detection rates.
Search strategies may be different for each type of abnormality,
so a system that tries to ﬁnd masses, microcalciﬁcations, and archi-
tectural distortions on mammograms has a difﬁcult task.
3.1.2. CAD status
Another categorization of CAD systems is between approved,
commercial systems, such as R2 Technology’s ImageChecker
(Hologic, Bedford MA, USA) and iCADx’s SecondLook (Nashua,
NH, USA) for mammography, and research systems that are often
clinically untested. Twenty-nine (20%) of the studies included in
this review used a commercial system, and in general these tended
to report worse performance than the studies of research systems
(e.g., signiﬁcantly worse sensitivity: 77% [speciﬁcity 66%] versus
89% [speciﬁcity 77%], P < 0.001). Commercial systems often suffer
from high number of false positive results, as described in previous
studies (e.g., [11,12]). This is not surprising because such systems
have had to prove that they are robust over large population ranges
to be accepted by approval bodies and purchasers; some decrease
in speciﬁcity may be considered an acceptable compromise to en-
sure higher sensitivity if it is thought better to produce false posi-
tive results than to miss disease cases [13]. Research systems have
usually been trialed only on a limited population, and many have
not been tested with data beyond the same population used to
train the system, as will be discussed further in Section 3.3. In such
situations, it can be easy to produce relatively impressive sensitiv-
ity and speciﬁcity results.
Two articles within the sample compared different commercial
CAD systems: Ellis et al. [14] looked at two mammography CAD
systems: iCADx’s SecondLook and R2’s ImageChecker. Ciatto et al.
[15] compared the performance of these two systems with an Ital-
ian system: Medicad’s Cyclopus. In both of these studies, R2’s sys-
tem performed better than iCADx’s system, and in Ciatto et al.,
Medicad’s system produced the best performance.
These established commercial systems can provide a benchmark
againstwhich to test newsystems, but their software version details
must be included because they are regularly upgraded with new
programming that offers improved performance. Another consider-
ation concerns the differing diagnostic thresholds that CAD systems
can use to produce their optimum results: some commercial
L.H. Eadie et al. / Journal of Biomedical Informatics 45 (2012) 390–397 393systemsoffer theuser a choiceof sensitivity–speciﬁcity settings, and
these too should be reportedwith any results. See recommendation 2
in Section 4.1.
3.1.3. CAD analysis methodology
CAD systems use various methodologies to perform their image
analysis. In this review sample, these included neural networks
(NN), discriminant analysis, regression, genetic algorithms, deci-
sion trees, clustering, fuzzy logic, support vector machines (SVM),
template matching and feature-based systems. Reports of the
range of commercial systems did not always describe their pro-
cessing features, presumably to protect proprietary information.
Most CAD systems used a single methodology, but some combined
different methods with the aim of improving results (14 papers;
10% of the sample). Other papers compared different methodolo-
gies to discover which performed best (n = 15; 10%).
NN were the most popular methodology used within CAD (33%
of the sample) and many different types of NN were used, includ-
ing back-propagation, self-organizing maps, probabilistic, radial
basis function, and learning vector quantization. SVM and discrim-
inant analysis were also popular, used in 16% and 15%, respectively.
Some CAD systems consisted solely of an algorithm or NN,
where any image analysis is done by radiologists (n = 10; 7%); their
ﬁndings and classiﬁcations are input into the system, which re-
turns a diagnosis of malignant or benign. Only by careful examina-
tion of the study report does it become clear that no image analysis
is actually performed by the CAD system. It is unclear how useful
this sort of system is; the time taken for radiologists to input the
image features following observation will obviously be additional
to the usual interpretation time, and many may not consider the
extra time worthwhile.
3.2. Study population
The population from which the study images are taken can have
a large effect on the results of testing: it has been noted that a sin-
gle CAD system will produce different sensitivities and speciﬁcities
with different testing case composition [16]. CAD trials frequently
include only small numbers of subjects (often due to the rarity of
the disease in question), so the power of the study must be care-
fully considered during trial design.
Another point to note is whether the study population is repre-
sentative of the clinical population; in this sample only 32% of
studies were undertaken using a representative sample of images.
Some studies use samples enriched with cancer cases, some are
without asymptomatic subjects. Alternatively, other studies look
only at ‘difﬁcult’ images (n = 11 studies, 7%), such as interval can-
cers, those missed by screeners, or images that went to arbitration
because readers did not agree about the diagnosis. Unsurprisingly,
these studies reported signiﬁcantly worse results than studies
using more commonly experienced images (mean ln DOR 0.8 ver-
sus 3.9, P < 0.001). Other studies will contain relatively easy-to-
spot lesions, and this type of population is likely to produce results
that are particularly favorable to CAD [16]. All of these population
choices allow the study to tell us something about the CAD system
being tested, but it does not mean that the results will necessarily
be applicable or transferable to standard clinical practice. See rec-
ommendation 3 in Section 4.1.
The review studies used images taken from patients collected
either prospectively (16%) or retrospectively (84%). Retrospective
data collection can increase efﬁciency, meaning that researchers
do not have to wait for subjects to be enrolled, making the whole
process simpler and quicker, but access to data stores is usually re-
stricted and the number of available images may not be large.
Many studies made use of databases of stored anonymised images,
such as the Digital Database for Screening Mammography (DDSM)[17] or the Mammographic Image Analysis Society (MIAS) database
[18]. These databases do not usually contain additional clinical
data beyond the age of the subject, and so demographic informa-
tion is frequently absent in the resulting reports. Another factor
arising from database use is that the diagnosis recorded in the
database is often accepted as the gold standard without any infor-
mation being provided about how the diagnosis was made (17% of
the sample). However, public databases do provide a means by
which CAD systems can be contrasted, by comparing results from
the same images generated by different systems, so they certainly
have a valuable place in CAD research.
The studies examined for this review have widely varying sam-
ple sizes, from the inclusion criteria minimum of 20 patients, with-
in which a single image can be resampled many times to boost
image numbers (e.g., [19,20]), to many thousands of patients in a
nationwide clinical trial (e.g., [21] with 222,135 subjects). This
has implications in terms of study power and the generalization
of results to wider populations; obviously, the bigger and more
representative of the overall population the sample, the better.
See recommendation 6 in Section 4.1.
3.3. Image input
The images used in these studies also vary: some CAD systems
use prespeciﬁed regions of interest (ROI) as their input (49% of the
sample) rather than whole images. ROI were manually selected by
radiologists (94%) or chosen as part of an automatic detection and
segmentation process built into the CAD software (4%; 2% of stud-
ies did not specify how the ROI were chosen). Some use a combina-
tion of these methods, with the radiologist clicking on a ‘seed’
point from which the program expands a segmentation border to
ﬁnd the extent of the tumor, and from there, the relevant ROI. Sys-
tems that work with ROI usually aim to determine whether the
suspicious region is malignant or benign; there was a signiﬁcant
correlation between ROI as input and type of CAD diagnosis
(P < 0.01). One could envisage such systems being used by a radiol-
ogist who has identiﬁed an unusual area on the image, but is un-
sure whether it is a cause for concern. See recommendation 4 in
Section 4.1.
Systems given ROI to analyze have signiﬁcantly better sensitiv-
ity than systems working with a full image (90% versus 82%,
P = 0.01), although with similar speciﬁcity. This is not surprising,
because such region restriction makes the whole task simpler for
the program. In fact, it could be argued that this type of CAD sys-
tem is performing a different task to lesion detection, and the
two types of system should not be directly compared.
3.3.1. Multiple image use
Within cancer diagnosis, images taken at a previous screening
session can be useful. One study analyzed prior images compared
with current images [22]. This focused on lesions that had been
missed by radiologists, and investigated whether a CAD system
could ﬁnd these lesions on current and prior mammograms. Each
set of images was examined individually and comparisons be-
tween results made afterwards by the authors. The CAD system
helped the physician ﬁnd more missed lesions than when working
alone.
Other sources of multiple images for analysis using CAD in-
cluded video and imaging protocols using contrast: there were sev-
eral studies of CT colonography and endoscopy which involved
CAD systems analyzing individual stills from a series of video
images. In general these performed very well, with greater than
90% accuracy in 7 of the 8 studies. Imaging using contrast infusion
with MRI or CT was performed before and during infusion, and
during the washout stage. All of the 12 studies had an accuracy
of 75% or above; half used a regression methodology.
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There are various experimental designs that have been used to
test CAD, including the use of image databases, historic controls
(pre-CAD implementation), crossover and sequential image read-
ings. This is linked with the study population and while the use of
prospective data collection is the ideal for trials, in some cases use
of a public database can be perhapsmore accurate: consider the case
of comparing diagnostic rates before and after CAD is introduced.
Changes in clinical processes or patient demographics must be
noted, because these might lie behind changes in results that might
otherwisebe attributed toCAD [16]. Variousother factors concerned
with the testing of CAD systems are discussed below.3.4.1. Gold standards
There were a range of gold standards against which the CAD
system results were tested. The majority of studies used histolog-
ical samples to verify the presence of cancer (see Fig. 4), with other
options being radiologist diagnosis, other imaging studies, results
as reported in a public database from where the images were
sourced, and a few studies did not report the source of the gold
standard diagnosis. It is clear that whatever form the gold standard
takes, details about it are required, so that its reliability can be
judged. The use of radiologists’ diagnosis as the gold standard
means it is possible that some cancers could be overlooked during
the reference viewing. As such, if a CAD system located these can-
cers, they would be counted as false positives rather than actually
being radiologists’ false negatives. External veriﬁcation (e.g.,
biopsy results, long-term follow-up) seems a sensible measure to
ensure that the gold standard diagnosis is accurate. See recommen-
dation 5 in Section 4.1.3.4.2. Data sampling and system validation
CAD systems usually have to be trained on a dataset containing
examples of all possible relevant features, and choice of data for
the training and testing sets is important. There are various
options:
 apparent: testing using the training set
 internal: testing using a similar dataset. This option includes
cross-validation, ‘leave-one-out’ and bootstrapping
 temporal: testing using a separate, prospectively collected data-
set from the same population setting
 external: testing using a separate data set collected from a dif-
ferent setting.
More than half of the studies (52%) used internal testing for their
CAD system. This method allows the available data to be resampled67%
17%
9%
4% 3%
Database 
entry
Histology
Imaging Unknown
Radiologist
Fig. 4. Gold standards used in the sample of CAD trials.and reused, which can be useful when working with limited data.
Cross-validation involves splitting the data into a minimum of two
sets: one for training and one for testing. Then the data is split again,
differently, and the sets are used oncemore, and so the process is re-
peated, with an average taken of all the results. Round-robin or
‘leave-one-out’ sampling uses all of the data for training except
one case, which is used for testing, and again uses an average of re-
sults from all possible data combinations. A limitation of cross-val-
idation is that the results are generated from models that do not
include the complete dataset. Bootstrapping can solve this problem;
it involves repeated sub-sampling (with replacement) of the data to
create a new set for training, and testing on cases from the original
data set that are not present in the new set. The process can be re-
peated and an average error calculated.
It is good practice to train the system, validate it, and then test it
using completely new and different data for each stage, where pos-
sible. In many cases, temporal testing is preferred to external, to
ensure the populations are similar, but external testing will provide
a more accurate idea of the performance of the system beyond the
test setting, which will be useful for those considering commercial-
ization. Both temporal and external validations can also provide
information about performance in populations over time (popula-
tion drift), which can be very useful clinically. See recommendation
6 in Section 4.1.
There were no signiﬁcant differences in results between the
different data sampling methods.
The review sample also contained six papers reporting on the
development and training of a CAD algorithm, with apparent test-
ing using the same training data (4%). It is difﬁcult to assess these
systems without publication of further testing results.
3.4.3. Inclusion of radiologists
SomeCADsoftware canbeusedas a stand-alone system,process-
ing imageswith little input required fromanoperator, butmost peo-
ples’ understanding of CAD is a system used by radiologists to assist
their diagnosis. A major decision for CAD study planning, therefore,
is whether to involve suitably experienced radiologists, either as a
direct comparator to test the system against or in a radiologist
with/without CAD design. Ideally, CAD software should be tested
in the same conditions in which it would be used clinically, which
would mean with radiologists.
In the review sample, there were signiﬁcantly more higher qual-
ity studies testing CAD being used by a radiologist than testing CAD
working alone (47% versus 20%, P = 0.01). This may be a result of the
type of trial that involves radiologists compared with trials where
just the CAD system and images are used: the former require more
organization and are likely to be scrutinized more closely.
The design of trials with radiologist involvement can pose a dif-
ﬁcult problem. The trial cannot be blinded if radiologists are asked
to incorporate a new piece of technology into their clinic. The very
presence of a system to aid diagnosis may cause radiologists to
consider their diagnoses more carefully than normal, and the pos-
sibility of carrying over behavior from the CAD arm of a trial to the
control arm (or vice versa) means that trial design, in particular
considering order effects, is a very important factor.
If radiologists are to look at images both with and without the
assistance of CAD, then a study design allowing for order and
memory effects should be considered, e.g., a crossover design. Such
effects, if not countered, can lead to unexpected results. Some stud-
ies compare the radiologists’ initial assessment (made without
CAD) to their ﬁnal assessment (made with CAD). This design could
exaggerate the impact of CAD because the baseline measurement
may be an underestimate of the radiologists’ true performance,
since they may economize on effort expended on the initial assess-
ment in the knowledge that a second look will be required before
the ﬁnal assessment; and secondly, any possible negative impact
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ally only adds to the number of detections. The test environment is
usually artiﬁcial and may lead to changes in radiologist perfor-
mance [16]. See recommendation 7 in Section 4.1.
There is also the question of user familiarity and compliance
with the instructions for using the system. A surprising number
of the studies that involved radiologists directly in the testing of
CAD systems did not report any type of training in the use of the
system (31%). Such software often has a steep learning curve,
and tests of CAD should allow radiologists to practice and become
accustomed to the system before their performance is ofﬁcially
measured [23]. It could be that training actually was provided in
the studies where it was not mentioned, or the radiologists were
already familiar with the system in question, but ideally participat-
ing radiologists’ previous experience with the CAD system before
testing should be reported. See recommendation 8 in Section 4.1.
Another interesting area for study is the interaction between
CAD and radiologists: whether and why radiologists ignore correct
CAD results, and whether and how CAD changes radiologists’
minds about their diagnoses. In a clinical-based trial, it can be dif-
ﬁcult to audit the eventual diagnoses made and the contribution of
the CAD system to those decisions. ‘Changing radiologist’s diagno-
sis’ has been reported as an outcome measure in some of the stud-
ies in the sample (e.g., [24]). In addition, while many research
systems are created concentrating on accuracy, they do not always
take into account how and when they would be used clinically.
Some thought about how CAD will ﬁt into clinical practice, radiol-
ogist methods, and analysis will undoubtedly save time and ex-
pense later on, should the system perform well enough to merit
wide-scale use, and may even improve the performance of radiol-
ogists with CAD through factors associated with ease of use.3.5. Performance measures
A variety of different outcome measures were reported by the
studies of CAD. Themost commonly usedwere sensitivity and spec-
iﬁcity, as in this review’s sample. The use of sensitivity and speciﬁc-
ity is supported by various guidelines for writing reviews of
diagnostic test studies [25–27]. Themost basic results are true posi-
tive, false positive, true negative, and false negative scores, which
can beused to derivemeasures such as positive andnegative predic-
tive values and overall accuracy. Also popular in the samplewas the
area under the receiver operating characteristic (ROC) curve, known
as Az or AUC. This could bewhole or partial (looking at the difference
in AUConly in a speciﬁc region of the curve) and fromaROC, free-re-
sponse ROC (FROC – for multiple lesions with conﬁdence ratings) or
a jackknife alternative FROC (JAFROC– formultiple-readermultiple-
case data) curve. Sometimes the curves alone were displayed on a
graph with no details on the AUC or any other measure that can be
derived from them. Other studies, mainly clinical tests, reported
cancer detection (essentially the same as sensitivity) and patient re-
call rates (many more patients are recalled for further testing than
actually are found to have cancer; this rate includes both true and
false positive cases). Other results reported included: time taken
to review the images, number of marks per image, reproducibility
of results byCADsystems, agreementbetweenCADand radiologists,
and whether the CAD results caused radiologists to change their
mind about their unaided diagnostic decisions. This last option can
provide valuable information about how radiologists use CAD,
whether CAD can highlight lesions that would otherwise be missed,
or whether correct CAD suggestions are overruled and rejected by
radiologists.
From the literature review’s initial retrieval of around 3300 ref-
erences, 730 (22%) of the abstracts reported sensitivity or speci-
ﬁcity (360 [11%] reporting both), 330 (10%) reported AUC, and100 papers (3%) reported sensitivity/speciﬁcity and AUC. Only
20 studies (0.6%) reported detection and recall rates.
In addition, results could be further divided up by cancer size and
visibility, tissue density and/or fattiness, radiologist experience, and
by institution. For cancers where there were often more than one
imageonwhich several lesions couldbe found, suchas lungor bowel
cancer, results were described as per image or per patient.
This wide array of result reporting options means that any com-
parison between studies must be done very carefully to ensure that
the results being examined are in fact equivalent and comparable.
See recommendation 9 in Section 4.1.3.6. Study quality and reporting
The quality of trial design and reporting is an area of wide var-
iation for CAD studies. See recommendations 10 and 11 in Section
4.1. The quality of the sample was assessed using the QUADAS tool
for assessment of diagnostic studies in systematic reviews [10].
From a possible total score of 14, the mean, median and mode
score of the studies was 10, with a range of 7–12. There were pro-
portionately more lower quality (score < 10) studies published in
conference proceedings than in journals (27% versus 9%;
P = 0.001). The proportion of lower scoring studies was greater
within research systems than within commercial systems (37%
versus 14%, P < 0.001), and 91% of low scoring studies concerned
research CAD compared with 74% of higher scoring studies. There
were more prospective studies in the higher scoring reports (21%
were prospective versus 4% prospective for lower scoring studies).
There were no signiﬁcant differences in sensitivity and speciﬁcity
associated with study quality (Fig. 5).
The implications of scoring study quality are varied. Lower
quality studies may have design ﬂaws or merely reporting deﬁ-
ciencies; it can be difﬁcult to determine which is the case. If the de-
sign suffers from bias, the results may be artiﬁcially inﬂated and
these factors must be considered when assessing studies.
Looking at the median study size (chosen to prevent studies
with very large populations skewing an average) for lower and
higher scoring studies, lower scoring studies used slightly fewer
subjects: 121 versus 150 for higher scoring studies.
A number of previous analyses looking at diagnostic studies
have noted that the quality of reporting varies considerably (e.g.,
[28,29]). This was also the case in this analysis: as an example,
the source of the gold standard diagnosis, against which the CAD
system was compared, was not described in 11% of studies,
whether as a result of being a database entry, or whether it was
simply not described at all. This means that in these studies there
are no details about whether the gold standard is reliable and a
suitable basis for comparison.
It is also worth mentioning that not all studies reported enough
information to create a basic 2  2 results table (containing true
positive, false positive, true negative, false negative). In this sam-
ple, 18% did not provide such a table, and did not report enough
information to allow it to be constructed.4. Discussion
Despite the huge amount of research into CAD to assist with the
analysis of numerous imaging modalities, there are still few ofﬁ-
cially approved and widely used systems, and the bulk of published
research covers the development of potential systems or initial
non-randomized, non-controlled trials, often using anonymised
patient scans stored in large open-access databases. The failure
of CAD to transfer into routine clinical use has been attributed to
questions about the systems’ efﬁcacy, accuracy, and added beneﬁt
[30]. Clinical use depends on physicians’ perception that they can
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performance. Meta-analyses, the pooling of data, and direct com-
parisons between CAD systems, which might help resolve these
questions, are problematic due to the various sources of heteroge-
neity described in this article. Care must be taken to ensure that
pooling of results does actually produce meaningful insights.
Can collective studies ever provide a true picture of CAD perfor-
mance? Each of the reviewed studies can only report their own re-
sults and together can provide only a general overview of the topic.
Small meta-analyses may ﬁnd a few comparable studies but will be
greatly restricted. The quality of papers included must be consid-
ered, possibly even to the extent of weighting study results by
quality. Some of the difﬁculties are due to the design of the sys-
tems, but there are factors related to the major sources of hetero-
geneity in CAD studies that researchers can take into account and
optimize to facilitate trial comparability.
4.1. Recommendations
We suggest that CAD researchers consider the following recom-
mendations to improve the quality and comparability of their
results:
1. A clear description of the CAD system’s aims, targets, and
methodology used should be provided so that others can eas-
ily determine these featureswhenwishing to compareor pool
results.
2. If using a commercial CAD system, report the software ver-
sion number and system sensitivity–speciﬁcity settings, so
that comparisons can take these details into account.
3. The patient population used should ideally be representative
of that found in clinical practice, and the CAD system should
be trained to look for all subtypes of the relevant cancer. If
the training population is enriched with cancer cases, the
CAD systemwill output a similar proportion of cancers when
used clinically and will therefore produce false positive
results. Similarly, it will learn about the existence and pro-
portions of cancer subtypes from the training data, so care
must be taken to ensure that this data contains cases appro-
priate to the clinical population. It is important to report the
prevalence of the disease in the chosen population, as this
has implications for various outcome measures.
4. Make it clear whether the CAD system uses ROI or whole
unedited images as its input. If ROI are used, then the user
interaction required should be described.
5. A veriﬁable gold standard should be chosen, a test that can
accurately provide a ground truth against which other diag-
noses can be assessed. For example, if radiologist diagnosis ischosen as the gold standard, then some period of follow-up
should be included in order to verify their diagnosis and
ensure that no lesions have been missed. Histology results
with patient follow-up are likely to form the best gold stan-
dard, although not necessarily the most convenient.
6. When determining a study’s sample size, consider the power
of study and also the ability to have separate groups for
training and testing of the CAD system. The more images,
the better, but if a small sample is all that is available, then
a statistically rigorous method such as cross-validation or
bootstrapping can be used.
7. The study design should be chosen to avoid order effects
where radiologists are asked to look at images more than
once. It can incorporate a delay and/or reordering of the
images. A cross-over design can help neutralize this sort of
bias.
8. Participating radiologists should be trained in CAD use and
have the opportunity to practice diagnosing with CAD before
a study begins. This will help counter any learning curve
effects, and show the real performance beneﬁt for radiolo-
gists using CAD.
9. The study should report results using commonly used com-
parable assessment measures. The simplest and potentially
most useful (other results can be calculated from these if
necessary) are true positive, true negative, false positive,
false negative, ideally presenting a 2  2 table of these
results. Other measures that would be useful include details
of the radiologist–CAD system interaction, such as CAD’s
effect on changing radiologist decisions and correct CAD
results rejected by radiologists.
10. Careful attention to reporting is required: aim for clarity and
completeness. Articles should be as informative as possible
and should attempt to answer obvious questions. Study key-
words should be considered carefully, anticipating possible
future searches for the research.
11. Checklists suchas Standards forReportingofDiagnosticAccu-
racy (STARD) [31] and QUADAS [10] should be consulted dur-
ing trial design and reporting. They provide criteria about
what should be included in a publication to produce complete
and informative papers. These factors should also be consid-
ered during trial design so that appropriate measures can be
built into the system testing.
If CAD studies were more standardized in their design and
reporting, and therefore more readily comparable, meta-analysis
would be feasible and it may be possible to achieve an idea of
the true value of CAD and its role in diagnosis.
5. Conclusions
The extreme heterogeneity of CAD systems analyzing diagnostic
cancer imaging, trial design, and variable reporting quality means
that it is difﬁcult to estimate the beneﬁt that CAD may offer. Some
of these problems can be addressed by researchers, and we have
provided recommendations for optimizing the design and report-
ing of CAD trials.
Appendix A. Supplementary material
Supplementary data associated with this article can be found, in
the online version, at doi:10.1016/j.jbi.2011.07.009.
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